Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00043277 · ClinicalTrials.gov registry record · Phase 2
Study Of Angiomax In Infants Under Six Months With Thrombosis
A Phase 2 study of Thrombosis, sponsored by The Medicines Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT00043277: Completed Phase 2 study of Thrombosis, sponsored by The Medicines Company.
NCT00043277 is a Phase 2 study of Thrombosis that has completed, run by The Medicines Company. The registered enrollment target is 25 participants, below the 469-participant average among 28 other Thrombosis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00043277, a Phase 2 study of Thrombosis, has completed, sponsored by The Medicines Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The goals of this study are: 1. To assess the safety of bivalirudin in infants under six months with arterial or venous thrombosis; 2. To determine the dose of bivalirudin required to achieve adequate anticoagulation as measured by the activated clotting time (ACT) or activated partial thromboplastin time (aPTT) in Infants Under Six Months with arterial or venous thrombosis; 3. To determine the outcome of patients on bivalirudin with respect to thrombus resolution and bleeding complications compared to patients on unfractionated heparin (UH) or low molecular weight heparin (LMWH).
Conditions Studied
Interventions
- DRUG Angiomax (bivalirudin)
Study Locations (1)
California
- Children's Hospital of Orange County - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2002-08 |
| Est. Completion | 2004-12 |
| Phase | Phase 2 |
What the finished NCT00043277 record still lists
NCT00043277 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 469-participant average among 28 other Thrombosis trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Thrombosis appearing as the primary indexed condition, and to 1 intervention - of which Angiomax (bivalirudin) is the first listed.
NCT00043277 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00043277 about?
NCT00043277 is a clinical study titled "Study Of Angiomax In Infants Under Six Months With Thrombosis". The goals of this study are: 1. To assess the safety of bivalirudin in infants under six months with arterial or venous thrombosis; 2. To determine the dose of bivalirudin required to achieve adequate anticoagulation as measured by the activated clotting time (ACT) or activated partial thromboplast...
What is the current status of trial NCT00043277?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2002-08. Estimated completion is 2004-12.
What conditions does trial NCT00043277 study?
This clinical trial studies the following conditions: Thrombosis.
What interventions are being tested in trial NCT00043277?
The interventions under investigation include: Angiomax (bivalirudin) (DRUG).
Who is sponsoring clinical trial NCT00043277?
This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00043277 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00043277's enrollment target sits among peer trials
25 17th of 28 higher than 12 of 28 other Thrombosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thrombosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"
COMPLETED · Phase 2
-
A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery
COMPLETED · Phase 2
-
Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion
COMPLETED · Phase 2
-
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RECRUITING
-
Positron Emission Tomography (PET) Imaging of Thrombosis
RECRUITING · Phase 1
-
Pharmacogenomics of Warfarin in Hispanics and Latinos
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia